Compugen Doses First Patient in Triple Immunotherapy Combination COM701, COM902 and Pembrolizumab Platinum Resistant Ovarian Cancer Proof-of-Concept Study

Compugen, a clinical-stage cancer immunotherapy company, has announced the successful dosing of the first patient in a study that aims to evaluate the effectiveness of a triple immunotherapy combination for treating platinum-resistant ovarian cancer. The study builds on previous clinical benefits reported in heavily pretreated platinum-resistant ovarian cancer patients who were treated with dual..